

# Per Karlsson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11613275/publications.pdf>

Version: 2024-02-01

48  
papers

7,419  
citations

185998

28  
h-index

205818

48  
g-index

48  
all docs

48  
docs citations

48  
times ranked

10609  
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	0.6	2,805
2	Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
3	Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. <i>Journal of Clinical Oncology</i> , 2016, 34, 927-935.	0.8	390
4	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1385-1393.	5.1	342
5	Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. <i>BMC Cancer</i> , 2013, 13, 1.	1.1	293
6	Absolute Risk Reductions for Local Recurrence After Postoperative Radiotherapy After Sector Resection for Ductal Carcinoma In Situ of the Breast. <i>Journal of Clinical Oncology</i> , 2008, 26, 1247-1252.	0.8	232
7	Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3613-3618.	0.8	184
8	Intracranial Tumors after Exposure to Ionizing Radiation during Infancy: A Pooled Analysis of Two Swedish Cohorts of 28,008 Infants with Skin Hemangioma. <i>Radiation Research</i> , 1998, 150, 357.	0.7	156
9	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1601-1610.	0.8	100
10	Cancer Incidence after Radiotherapy for Skin Haemangioma During Infancy. <i>Acta Oncologica</i> , 1995, 34, 735-740.	0.8	99
11	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009, 18, 4442-4456.	1.4	99
12	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. <i>PLoS Biology</i> , 2011, 9, e1001199.	2.6	91
13	Clinical Implications of Gene Dosage and Gene Expression Patterns in Diploid Breast Carcinoma. <i>Clinical Cancer Research</i> , 2010, 16, 3860-3874.	3.2	85
14	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, R33.	2.2	78
15	Socio-economic factors and breast cancer survival – a population-based cohort study (Sweden). <i>Cancer Causes and Control</i> , 2005, 16, 419-430.	0.8	77
16	Soft tissue sarcoma after treatment for breast cancer. <i>Radiotherapy and Oncology</i> , 1996, 38, 25-31.	0.3	74
17	Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 3222-3229.	0.8	74
18	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011, 13, R110.	2.2	71

#	ARTICLE	IF	CITATIONS
19	Breast Cancer Risk after Radiotherapy in Infancy: A Pooled Analysis of Two Swedish Cohorts of 17,202 Infants. <i>Radiation Research</i> , 1999, 151, 626.	0.7	64
20	Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma. <i>International Journal of Cancer</i> , 2014, 134, 1617-1629.	2.3	57
21	Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 645-657.	1.1	47
22	Long-term inequalities in breast cancer survival – a ten year follow-up study of patients managed within a National Health Care System (Sweden). <i>Acta Oncologica</i> , 2008, 47, 216-224.	0.8	40
23	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 105-116.	3.0	40
24	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 956-964.	2.9	38
25	Clinical relevance of breast cancer-related genes as potential biomarkers for oral squamous cell carcinoma. <i>BMC Cancer</i> , 2014, 14, 324.	1.1	36
26	Long-term symptoms after radiotherapy of supraclavicular lymph nodes in breast cancer patients. <i>Radiotherapy and Oncology</i> , 2012, 103, 155-160.	0.3	35
27	Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer. <i>BMC Cancer</i> , 2008, 8, 254.	1.1	33
28	Breast cancer risk and possible mechanisms of radiation-induced genomic instability in the Swedish hemangioma cohort after reanalyzed dosimetry. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2015, 775, 1-9.	0.4	33
29	Common variants of the <i>BRCA1</i> wild-type allele modify the risk of breast cancer in <i>BRCA1</i> mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 4732-4747.	1.4	32
30	Prognostic Significance of <i>BIRC5</i> / <i>Survivin</i> in Breast Cancer: Results from Three Independent Cohorts. <i>Cancers</i> , 2021, 13, 2209.	1.7	29
31	Evidence for <i>SMAD3</i> as a modifier of breast cancer risk in <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2010, 12, R102.	2.2	25
32	Outcome of Reproduction in Women Irradiated for Skin Hemangioma in Infancy. <i>Radiation Research</i> , 1998, 149, 202.	0.7	24
33	Dose-Response Relationship for Parathyroid Adenoma after Exposure to Ionizing Radiation in Infancy. <i>Radiation Research</i> , 2002, 158, 418-423.	0.7	20
34	Breast cancer risk among Swedish hemangioma patients and possible consequences of radiation-induced genomic instability. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2009, 669, 48-55.	0.4	20
35	Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up. <i>British Journal of Cancer</i> , 2022, 126, 1145-1156.	2.9	20
36	Genome-wide multi-omics profiling of the 8p11-p12 amplicon in breast carcinoma. <i>Oncotarget</i> , 2018, 9, 24140-24154.	0.8	19

#	ARTICLE	IF	CITATIONS
37	A 17-marker panel for global genomic instability in breast cancer. <i>Genomics</i> , 2020, 112, 1151-1161.	1.3	18
38	Intracranial Tumors after Radium Treatment for Skin Hemangioma during Infancy: A Cohort and Case-Control Study. <i>Radiation Research</i> , 1997, 148, 161.	0.7	15
39	Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 285-295.	0.4	15
40	Clonal relatedness in tumour pairs of breast cancer patients. <i>Breast Cancer Research</i> , 2018, 20, 96.	2.2	14
41	Breast cancer risk after radiation treatment at infancy: potential consequences of radiation-induced genomic instability. <i>Radiation Protection Dosimetry</i> , 2011, 143, 375-379.	0.4	9
42	Postoperative radiotherapy after DCIS: Useful for whom?. <i>Breast</i> , 2017, 34, S43-S46.	0.9	8
43	Positive sentinel node in luminal A-like breast cancer patients - implications for adjuvant chemotherapy?. <i>Acta Oncologica</i> , 2019, 58, 162-167.	0.8	8
44	Genetic alterations associated with multiple primary malignancies. <i>Cancer Medicine</i> , 2021, 10, 4465-4477.	1.3	7
45	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 959-967.	2.9	5
46	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512.	3.2	5
47	Reliability of estimating left ventricular ejection fraction in clinical routine: a validation study of the SWEDEHEART registry. <i>Clinical Research in Cardiology</i> , 2023, 112, 68-74.	1.5	3
48	A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1619-1628.	1.1	1